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Abstract
Background: Urinary biomarkers have the potential to improve the early detection of bladder cancer. Most of the various
known markers, however, have only been evaluated in studies with cross-sectional design. For proper validation a
longitudinal design would be preferable. We used the prospective study UroScreen to evaluate survivin, a potential
biomarker that has multiple functions in carcinogenesis.
Methods/Results: Survivin was analyzed in 5,716 urine samples from 1,540 chemical workers previously exposed to
aromatic amines. The workers participated in a surveillance program with yearly examinations between 2003 and 2010. RNA
was extracted from urinary cells and survivin was determined by Real-Time PCR. During the study, 19 bladder tumors were
detected. Multivariate generalized estimation equation (GEE) models showed that b-actin, representing RNA yield and
quality, had the strongest influence on survivin positivity. Inflammation, hematuria and smoking did not confound the
results. Survivin had a sensitivity of 21.1% for all and 36.4% for high-grade tumors. Specificity was 97.5%, the positive
predictive value (PPV) 9.5%, and the negative predictive value (NPV) 99.0%.
Conclusions: In this prospective and so far largest study on survivin, the marker showed a good NPV and specificity but a
low PPV and sensitivity. This was partly due to the low number of cases, which limits the validity of the results. Compliance,
urine quality, problems with the assay, and mRNA stability influenced the performance of survivin. However, most issues
could be addressed with a more reliable assay in the future. One important finding is that survivin was not influenced by
confounders like inflammation and exhibited a relatively low number of false-positives. Therefore, despite the low
sensitivity, survivin may still be considered as a component of a multimarker panel.
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Introduction
Bladder cancer is one of the leading cancers in the U.S. and in
Europe. In Germany, the incidence is about 29,000 cases per year
[1]. Because of the high rate of tumor recurrence, close monitoring
and repeated use of therapies are necessary. As a consequence,
bladder cancer is the most costly cancer disease [2]. Tumors of the
urinary bladder can be caused by occupational exposure to
aromatic amines but tobacco smoking is considered to be the
strongest contributor to the development of these malignancies [3].
The availability of effective treatments, the access to the target
organ via urine, and the relatively good overall survival makes
bladder cancer a candidate for screening programs in high-risk
populations [4]. Unfortunately, cystoscopy, which is the current
gold standard for bladder cancer detection, is an invasive and
rather painful method. In some countries high costs may also play
an important role [4]. These facts preclude cystoscopy from being
used in screening cohorts. In contrast, urinary tumor markers are
non-invasive tools to detect bladder cancer. Typical markers are
proteins, RNA, DNA, metabolites, or cellular features, which have
the advantage that they can be determined in urine samples [5,6].
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6Of the numerous known markers, however, only few have been
tested in prospective studies or trials and were successful to be
approved by the FDA. Consequently, more longitudinal studies
are necessary to prove the value of these markers for cancer
screening and clinical decision-making [7].
Survivin is a relatively small protein of 16.4 kDa encoded by the
gene BIRC5 [8,9]. Its three-dimensional structure was resolved and
suggested an adaptor or docking function [10,11]. Binding to a
number of other macromolecules has in fact been demonstrated
and survivin emerged as a central node in multiple cellular
networks [9,12–14]. While survivin belongs to the inhibitor of
apoptosis (IAP) gene family its functions are not restricted to a
regulatory role in apoptosis. Other functions are the control of cell
division and chromosome segregation, promotion of proliferation,
stress response and angiogenesis, and it plays a role in metastasis
[9,15–19]. Dysregulation of survivin would therefore affect four of
the six so-called ‘hallmarks of cancer’ in the model of
tumorigenesis described by Hanahan and Weinberg, suggesting
a central function of survivin in carcinogenesis and tumor
progression [20].
The multiple mechanistic roles of survivin are also reflected in
its widespread occurrence in all stages of tumor development,
though with preference to later stages in several cancers [21–25].
Survivin is overexpressed in most human cancers but rarely
detectable in healthy adult tissues [8,26]. It has, therefore, been
proposed as a potential tumor marker and target for therapy
[8,27]. Due to the fact that non-invasive detection in urine samples
is possible, survivin could be used specifically for screening of
urogenital malignancies. Several studies, mostly of cross-sectional
design and with a relatively limited number of cases, have
demonstrated that survivin is a promising candidate for further
validation in longitudinal studies [28–34]. Shariat et al. performed
a larger prospective study on recurrent bladder cancer that was
based on immunohistochemical staining of tumor samples.
Herein, survivin improved the prediction of recurrence and
survival in a subgroup of patients [21].
In the present study, we determined survivin in the prospective
screening cohort UroScreen [35–37] using an mRNA-based assay
in order to validate its function as a tumor marker for early
detection of bladder cancer.
Results
The participants of the UroScreen cohort were active or retired
chemical workers with former exposure to aromatic amines as
described previously [35–37]. They were examined between
September 2003 and June 2010. Urine samples were collected
for urine status, cytology, the determination of NMP22H,
chromosomal aberrations (UroVysion
TM), and – if sufficient
material was available – for survivin [36,37]. For survivin
measurements 5,716 urine samples could be obtained from
1,540 participants (Tables 1 and 2). Median age of the cohort
was 62 years (range 27–90 years). Of the 1,540 persons, 18
developed tumors, including one person who developed two
tumors during the study resulting in 19 tumors in total for the
investigation of survivin. For another two cases no suitable urine
sample was available for survivin determination. Of the 19 tumors,
three were papillomas, eleven high-grade, and five low-grade
tumors (Table 3). Cytology detected eight tumors. The survivin
assay detected four tumors, all of which were high-grade. Three of
Table 1. Characteristics of male participants of UroScreen with former occupational exposure to aromatic amines.
Characteristics Category All Cases Non-cases
Subjects 1540 18* (1.2%) 1522 (98.8%)
Age in 2010 (years) Median (range) 62 (27–90) 68 (43–80) 62 (27–90)
Age at diagnosis 66 (38–76)
Smoking status at baseline Never 424 14 420
Ever 1116 4 1102
Former bladder cancer at baseline 18 2 16
*One person with two tumors.
doi:10.1371/journal.pone.0035363.t001
Table 2. Characteristics of urine samples of the UroScreen study.
Characteristics Category All Cases Non-cases
Number of urine samples 5716 (100%) 75 (1.3%) 5641 (98.7%)
Test result for survivin
True negative False positive
5435 206
Creatinine* N 4806 63 4552 191
Median 1.15 1.01 1.15 1.19
(Inter-quartile range) (0.68–1.64) (0.57–1.53) (0.68–1.64) (0.76–1.56)
b-actin Median 16600 24600 15900 73600
(Inter-quartile range) (5770–48950) (9850–77600) (5540–45700) (20880–221000)
*Creatinine was only available for the 4806 samples of subcohort A.
doi:10.1371/journal.pone.0035363.t002
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detected by survivin and NMP22 only (Figure 1).
The tumor marker survivin was determined by an mRNA-
based assay that was not commercially available. During the seven
years of this longitudinal study, unforeseen events regarding the
reliability and availability of assay components (RNA isolation kits
from Qiagen and Invitek, survivin reagents from FDI and IPA)
prompted us to modify the assay design twice, leading to three
different assay variants (Qiagen/FDI, Invitek/FDI, Invitek/IPA).
We standardized the survivin copy numbers and could demon-
strate by using a multivariate generalized estimation equation
(GEE) model that the assay variants did not confound the test
results when implementing the standardized survivin copy
numbers (Table 4). All other results were, therefore, derived from
the standardized values.
Potential predictors of a positive survivin result were explored as
shown in Table 4. Indicators of infection and inflammation
(leukocytes), hematuria, or factors like age, smoking, or previous
bladder cancer did not show a significant effect on survivin levels.
The ‘concentration’ (specific density) of the urine sample, reflected
in the urinary creatinine concentration, tended towards an inverse
correlation with survivin, but this influence was not significant. As
expected, bladder cancer observed during UroScreen was a
predictor of positive survivin tests (OR 2.54, 95% CI 1.02–6.33).
b-actin (OR 3.11, 95% CI 2.51–3.85) was an effect modifier,
indicating a strong influence of the amount and quality of the
recovered mRNA on the PCR performance. A tenfold increase in
the copy numbers of b-actin was associated with a threefold higher
probability of a positive survivin test. We tested whether b-actin
was correlated with urine density by calculating the Spearman’s
rank correlation coefficient. There was a significant but only weak
association of b-actin copy numbers with urinary creatinine as a
proxy of urine density (rs 0.17, 95% CI 0.12–0.23).
The cancer-predictive values for survivin are listed in Table 5.
Calculations were based on the test results obtained in urine
samples from the last screening round before diagnosis. Survivin
reached a sensitivity of 21.1% for all tumor entities, 25.0% for all
tumors but without papillomas, and 36.4% for high-grade tumors
only. It did not detect any of the five low-grade tumors. The
specificity was 97.5% in all (sub)groups (all tumors, tumors without
papillomas, high-grade, and low-grade tumors). The positive
predictive value (PPV) reached 9.5% in all groups, whereas the
negative predictive value (NPV) ranged between 99.0 and 99.7%.
Receiver operating characteristic (ROC) analyses were per-
formed with standardized survivin levels from the last screening
round before diagnosis and adjusted for log10 (b-actin) and age in
10-year classes. They resulted in area under curve (AUC) values of
0.74 (95% CI 0.61–0.86) for all tumor entities (Figure 2), 0.75
(95% CI 0.60–0.89) for all tumors without papillomas, 0.80 (95%
CI 0.66–0.94) for high-grade tumors, and 0.66 (95% CI 0.36–0.96)
for low-grade tumors only. To judge the performance of the assay
variants, we calculated adjusted ROC curves for each variant. The
resulting AUCs were 0.70 (95% CI 0.34–1.00) for Qiagen/FDI,
0.80 (95% CI 0.54–1.00) for Invitek/FDI, and 0.79 (95% CI 0.67–
0.91) for the assay variant Invitek/IPA.
Possible reasons for negative test results in cases are compiled in
Table 6. The last samples of cases 5 and 10 were obtained 26 and
18 months before tumor diagnosis, respectively. Case 8 showed a
positive test result 14 months before diagnosis but the sample
shortly before diagnosis was negative. All other false-negative
results were in cases with papillomas and low-grade tumors; 31%
were associated with a low density of the collected urine indicated
by low creatinine (,0.50 g/l), and another 20% were likewise
associated with low RNA integrity as indicated by b-actin levels
,2,500 copies. In comparison, 15% and 11% of all true-negative
samples in the last screening round were associated with low
creatinine and low b-actin, respectively.
Discussion
While numerous potential markers have been described for the
early detection of bladder cancer, none so far have been
implemented in clinical guidelines for screening or clinical
follow-up on recurrence. Ideally, marker assays suitable for clinical
practice should be robust and cheap as well as fast and in an easy-
to-use format, e.g., a point-of-care test [38]. However, before the
assay format can be optimized, the performance of the marker
itself has to be evaluated. For molecular markers like survivin the
Figure 1. Venn diagram of all cases detected in UroScreen and correlation with marker results. A total of 19 tumors were detected in 18
cases. Survivin, cytology, NMP22, and UroVysion detected 13 of the tumors. *For two additional tumors (number 1 and 12) no sample was available
for survivin determination.
doi:10.1371/journal.pone.0035363.g001
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performance with currently available assays in bladder cancer
screening has been demonstrated to be comparable with or better
than approved tests. In UroScreen, we determined survivin with a
relatively complex assay wherein positive test results were not
followed-up with cystoscopy. Overall, survivin was detected in
particular in high-grade bladder cancer and its performance was
comparable to the other markers tested. However, mRNA
integrity was an important modifier of positive test results, and
therefore a more robust test should be developed.
To prove the value of new markers for clinical decision-making,
their performance has to be assessed in longitudinal studies and
clinical trials [7]. UroScreen was a prospective cohort study with
more than 1,500 chemical workers aimed to assess NMP22,
UroVysion, and survivin as tumor markers [36,37]. It was the first
prospective study that investigated the performance of survivin in
the early detection of bladder cancer. For 19 of the bladder tumors
that were detected during the conduct of the study sufficient
sample material was left for survivin determination. The low
incidence of bladder cancer in UroScreen as well as in the general
population is a critical issue for bladder cancer screening [4].
UroScreen was established as an extension of an already
established surveillance program in chemical workers [35]. The
initial power calculations were based on former data showing at
Table 4. Potential predictors of a positive survivin test result based on GEE models that included only urine samples with
complete information on all variables (190 positive survivin tests in 4546 samples from 1273 participants of UroScreen).
Variable at sampling Category N (Npos) OR 95% CI
Leukocytes None 1369 (50) 1
Traces 2884 (110) 0.82 0.57–1.17
Non-abundant and abundant 293 (30) 0.80 0.47–1.39
Hematuria None or traces 3584 (140) 1
Microhematuria and gross hematuria 962 (50) 1.08 0.76–1.53
Creatinine ,0.5 g/l 733 (30) 1.29 0.84–1.99
0.5–2.5 g/l 3567 (151) 1
.2.5 g/l 246 (9) 0.76 0.39–1.50
Log10 (b-actin) 4546 (190) 3.11 2.51–3.85
Age in 10 years 4546 (190) 1.09 0.95–1.25
Smoking status Never 1302 (52) 1
Ever 3244 (138) 11.04 0.75–1.45
Prevalent bladder cancer None 4492 (189) 1
Yes 54 (1) 0.21 0.03–1.46
Bladder cancer* None 4506 (186) 1
Yes 40 (4) 2.54 1.02–6.33
Assay** Qiagen/FDI 876 (28) 1
Invitek/FDI 1947 (87) 1.17 0.75–1.84
Invitek/IPA 1723 (75) 1.01 0.64–1.58
This analysis was performed with samples of subcohort A only because not all parameters were available for the full data set. Npos: number of samples positive for
survivin, OR: odds ratio, CI: confidence interval.
*Bladder cancer detected during UroScreen.
**After standardization.
doi:10.1371/journal.pone.0035363.t004
Table 5. Cancer predictive values of the last survivin test before diagnosis of bladder cancer.
Result All tumors Tumors without papillomas High-grade Low-grade
N=19 N=16 N=11 N=5
True positive 4 4 4 0
False negative 15 12 7 5
True negative 1484 1484 1484 1484
False positive 38 38 38 38
Sensitivity 21.05 25.00 36.36 -
Specificity 97.50 97.50 97.50 97.50
Positive predictive value 9.52 9.52 9.52 -
Negative predictive value 99.00 99.20 99.53 99.66
doi:10.1371/journal.pone.0035363.t005
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Currently, the incidence in this original high-risk cohort has
reached a level closer to that of the general population due to the
ban of carcinogenic aromatic amines from use in the chemical
industry decades ago. It is further likely that technological progress
and measures to improve work safety contributed to lowering the
bladder cancer incidence in this cohort of workers from two large
chemical companies. In addition, the median age of the
UroScreen cohort in 2010 was 62 years, whereas the median
age for bladder cancer for men in Germany was 72 years [1].
It has been shown before that survivin expression is higher and
more frequent in high-grade tumors or later stages of cancer
development [21,23–25]. In accordance with this observation,
survivin did not detect cases with papilloma or low-grade bladder
cancer in UroScreen, whereas the sensitivity was better for high-
grade tumors. If this could be confirmed, survivin might be a
useful adjunct for the follow-up of patients with faster growing
tumors where detection should be as early as possible. Here, a
non-invasive marker panel would be a promising approach to
detect recurrence sooner and reduce the number of cystoscopies
[40]. Nevertheless, individual molecular markers are currently
lacking sufficient sensitivity to replace cystoscopy [38].
The low number of incident cases limited the power of the study
to assess the performance of the tumor markers and contributed to
their low PPVs. Previously published studies showed specificities
between 88% and 100% and sensitivities between 53% and 100%
[28–30,32–34]. While our results showed a similar specificity
(98%) the sensitivity (21%) was markedly lower in this cohort
study. In part, this may be due to the different assays applied. The
main reason for the differences most likely is, however, the cross-
sectional study design of the other studies [41]. Major shortcom-
ings are the lack of consideration of the dimension time in order to
calculate predictive values, and a potential selection bias because
cases and controls have been recruited from different populations.
The longitudinal and thus prospective design of the UroScreen
study avoids this bias. It also represents a setting that is closer to
clinical practice.
We observed various reasons that might be responsible for the
fact that cases were not detected in our cohort study. A lack of
compliance in a voluntary screening study is a typical problem that
influences the early detection of cases. For most of the participants
of the study, samples were not available for each consecutive year.
In several cases, the difference between sample acquisition and
tumor diagnosis was more than twelve months, in one case even 26
months. It can be expected that an increase of marker levels is less
Table 6. Selected sample characteristics of false-negative cases.
Case number
1 Months before diagnosis Histopathology Quality of urine Quality of RNA
2 Low-grade Creatinine low
3 Low-grade b-actin low
4a Papilloma Creatinine low
52 6
7
8 0/14
2
10 18 b-actin low
11 Low-grade Creatinine low b-actin low
13
14 Low-grade
15
16 Papilloma
17 Papilloma
18 Low-grade
20 Creatinine low
1For cases 1 and 12 no samples were available for survivin determination.
2Negative at last (0 months), positive at previous screen (14 months).
doi:10.1371/journal.pone.0035363.t006
Figure 2. ROC curve for log10 (survivin) in the last screening
round before diagnosis, adjusted for log10 (b-actin) and age in
10-year classes. Analysis was performed for all tumors entities. The
resulting area under curve (AUC) was 0.74 with a 95% CI (confidence
interval) of 0.61–0.86.
doi:10.1371/journal.pone.0035363.g002
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and diagnosis. Another problem was that participants frequently
voided urine shortly before they arrived for an appointment and
therefore the urine collected on-site was insufficient in quality
and/or quantity for some of the marker tests. This kind of urine
was typically associated with low creatinine, a low number of
sedimented cells, and low b-actin.
In terms of confounding, survivin was less influenced than
NMP22 and UroVysion by urine status [36,37]. According to the
GEE model, creatinine and leukocytes did not influence the test
results for survivin. As bladder infections are frequently observed
in the elderly, it is important that inflammatory processes do not
influence a tumor test. This is an advantage the survivin assay has
in particular over NMP22, which is known to be frequently false
positive when participants suffer from infections. It was reflected in
the lower number of false-positive results of the survivin assay
compared to the NMP22 assay [37]. Despite the limited sensitivity
the relatively high specificity might allow survivin to be added to a
marker panel. It is important to note that positive survivin tests did
not result in a recommendation for cystoscopy. As a result, there is
a possibility that a few tumors might have remained undetected
and that we underestimated the performance of survivin. This
impairs the comparison with the performance of the FDA-
approved tests, i.e. NMP22 and UroVysion. The survivin assay
was positive for one case (4b) that was not detected by cytology or
UroVysion. Survivin was also positive for case number 8, which
was not detected by the cell-based assays 14 months before
diagnosis. Both cases were additionally tested positively by
NMP22. However, more cases would be required to prove the
point that expression-based markers like survivin might comple-
ment the cell-based assays UroVysion and cytology.
A specific issue with the quantification of survivin was the
difficulty to maintain the quality of a still experimental assay over a
period of several years. This can be a design-specific problem of
prospective cohort studies in comparison to cross-sectional studies.
Problems due to changes of the original RNA isolation kit and the
discontinuation of the production of assay reagents by the original
supplier resulted in three assay variants that led to different cut-off
values for survivin positivity. The discontinuities prevented the
determination of an optimized overall cut-off for the complete data
set. We normalized the copy numbers and implemented the assay
into the GEE model as potential confounder in order to test if
residual confounding could be found with the standardized
survivin data. The assay did not influence the test results but b-
actin turned out to be a significant modifier of the test results. It
appears possible that the specificity of survivin was reduced if more
of the urine samples had been higher concentrated. However, the
concentration of b-actin was not simply a function of urine density
because the correlation with creatinine was weak, indicating that
other factors like mRNA integrity may have contributed to the
performance of b-actin in the PCR reactions.
Besides these unforeseen methodological factors that influenced
the assay, the widely used mRNA format to detect survivin also
contributed to the overall performance of the assay. The RNA
integrity assessed by copies of b-actin was evaluated as the
strongest influence on the test results. The rationale behind the use
of an mRNA-based assay for survivin was to be able to detect even
weak signals of survivin that are present in the small numbers of
exfoliated urothelial cells. PCR and RT-PCR are elegant and well-
established methods to amplify and quantify very small amounts of
nucleic acids. Nonetheless, the low stability of mRNA in general,
even with the addition of RNase inhibitors, limits the applicability
of such assays for samples collected outside the controlled
conditions of a laboratory setting. There are better RNase
inhibitors available nowadays that would even dispense with the
necessity of sample freezing [42]. But the addition of these
preservatives to the sample has to be immediate. A possible way to
avoid delays would be a special collection tube, similar to those
used for blood collection, which already contains the preservative.
Another problem inherent to the survivin assay we used was the
nonlinearity caused by the two PCR-based amplification steps that
limited the accuracy of quantification and strategies for normal-
ization. Even applying b-actin, which served as an internal control,
for correction was not always sufficient to compensate for the large
variations in mRNA content in the samples, probably because of
the additional preamplification step of the survivin assay. For that
reason, for clinical settings under real life conditions, more stable
molecules like proteins might be better targets. While a PCR-like
amplification of proteins is not possible, ELISA-based assays can
achieve very good sensitivities and are now available for survivin in
better quality than at the onset of the UroScreen study.
To date, UroScreen is the largest prospective study to evaluate
survivin for the early detection of bladder cancer in a cohort of
asymptomatic participants. Despite the low number of incident
cases, valuable information has been gained on the performance of
the mRNA-based assay of survivin, technical challenges, influence
of confounders, and cancer predictive values. A more robust assay
would greatly benefit the marker and its use in clinical practice.
Survivin may have the potential to improve detection, especially of
high-grade tumors; its sensitivity, however, rests on only four
tumors (of 19) that were detected with three different assay
variants. The high specificity implies that survivin might be
considered to serve as part of a multimarker panel to complement
other markers but further validation in a prospective study with
more cases is warranted. Testing survivin within a cohort of
patients with a high risk of recurrent tumors would be a promising
approach.
Materials and Methods
Study population and diagnosis of tumors
Participants were recruited from the ODIN (Organisations-
dienst fu ¨r nachgehende Untersuchungen) cohort within the frame
of a surveillance program of the statutory accident insurance of the
chemical industry that offers yearly examinations of active and
retired workers who have been exposed to aromatic amines. From
September 2003 to June 2010 1,609 male workers at two large
chemical sites in Germany (subcohort A: BASF, Ludwigshafen;
subcohort B: Bayer, Leverkusen) participated in the UroScreen
study. 1,540 of those provided sufficient sample material for
survivin measurements. A questionnaire was applied to document
smoking habits and relevant diseases. All participants gave written
informed consent. The study was approved by the ethics
committee of the University of Tu ¨bingen (No. 1/2003V).
As the other tumor tests (cytology, NMP22H, UroVysion
TM)
applied in UroScreen were approved in contrast to survivin, it had
lower priority when sample material was limited. Therefore, only
5716 of the 7091 urine samples were available for survivin
measurements. Characteristics of the cohort are summarized in
Tables 1–2 and are described in more detail elsewhere (Pesch et
al., submitted and [37]). Positive test results for cytology,
NMP22H, or UroVysion
TM resulted in a recommendation for a
cystoscopic examination, while positive results for the non-
approved survivin assay did not.
As of November 2011, 21 tumors in 20 persons were detected
by cystoscopy and confirmed by reference pathology. For 18 of the
cases (19 tumors) urine samples were available for survivin
determination. One case had two tumors (4a and 4b in Table 3).
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corresponding urine samples (last screening round before diagnosis
of a tumor) are depicted in Table 3 and in [37].
Urine collection
Urine samples were collected on site at the chemical plants in
Ludwigshafen and Leverkusen. For survivin determination,
samples of 40–50 ml spontaneously voided urine were centrifuged
in a swinging bucket rotor at 5006 g for 10 minutes at 10uC.
Supernatant was carefully removed and cell pellets were mixed
with 500 ml Lysis Solution R (Invitek, Berlin, Germany), which
contains RNase inhibitors. Finally, the cell sample was frozen at
220uC and sent to the laboratory in Bochum where they were
stored until RNA isolation. Handling of samples for determination
of urine status and other markers is described below.
Urine status and assessment of hematuria
In all samples the urine status was determined in fresh urine
(before centrifugation) as described previously [36]. Urinary
creatinine was determined with the CREA plusH test (Roche
Diagnostics, Mannheim, Germany). Erythrocytes, hemoglobin
(Hb), leukocytes, albumin and other parameters were determined
with Combur 10 testH strips (Roche). In addition, erythrocytes and
leukocytes were also determined semi-quantitatively in urine
sediment. Creatinine measurements were available for subcohort
A only (4806 samples). For 4546 samples of these, complete
information on all parameters (erythrocytes, leucocytes, etc.) was
available.
NMP22H, UroVysion
TM, and cytology
Nuclear matrix protein 22 (NMP22) was determined quantita-
tively with the NMP22H ELISA kit (Matritech/Alere GmbH,
Ko ¨ln, Germany) according to the manufacturer’s protocol. The
cut-off for positive results was set to 10 units/ml. Chromosomal
instability in sedimented urothelial cells was assessed using the
UroVysion
TM Bladder Cancer Kit (Abbott Laboratories, Abbott
Park, IL). The test was considered positive if at least four nuclei
had three signals of two or three chromosomes (3, 7, and 17) or at
least 12 nuclei showed a signal for the 9p21 locus. Urinary
cytology was performed as described previously [36,43].
RNA isolation and survivin assays
Quantification of survivin was based on Real-Time PCR with
mRNA isolated from exfoliated urothelial cells in urine. For the
determination of survivin three variants of the mRNA-based assay
were employed. The variations were a consequence of changes by
the manufacturers of the RNA isolation kit and the RT-PCR
reagents, respectively. Initially, the protocol and reagents for the
survivin assay were provided by Fujirebio Diagnostics, Inc. (FDI,
Malvern, PA). The FDI protocol recommended the RNeasy Mini
Kit (Qiagen, Hilden, Germany) for RNA isolation. This kit,
however, is not optimized for the very small amount of RNA that
is usually retrieved from the low number of cells obtained from
40–50 ml of urine, leading to mostly low yields. A slight change in
one of the components of the kit in 2005 led to a further drop in
RNA yield. For that reason, it was replaced by an alternative
isolation kit (InviTrapH Spin Cell RNA Mini Kit) that produced
better and more consistent yields.
In 2007, FDI discontinued the production of reagents for the
Real-Time PCR assay. This prompted another change in the assay
procedure in 2008. Because no other source was available, we had
to design and produce some of the assay components ourselves (in
the following called ‘‘IPA assay’’). Slight differences in the primers
and probes of the Real-Time PCR assay consistently led to higher
copy numbers of survivin compared to the original FDI assay. The
three assay variants are as follows:
Variant 1 (Qiagen kit/FDI assay)
This variant was used from September 2003 until October
2005. RNA isolation was performed with RNeasy Mini Kits
(Qiagen) according to the manufacturer’s protocol. Reverse
transcription of mRNA, preamplification, and quantitative Real-
Time PCR were done as described by Kenney et al., except that
the reaction volumes of each step were cut in half to 25 ml [33].
Primers, reagents, and positive controls were provided by FDI at
no charge. In contrast to the published assay, instead of an ABI
PRISM Sequence Detection System a LightCycler II system
(Roche) was used. To be able to use the capillaries of the
LightCycler system it was necessary to add bovine serum albumin
(BSA, AppliChem, Darmstadt, Germany) to the TaqMan
reaction, with a final concentration of 0.16 mg/ml. The cut-off
for survivin-positive samples was set to 10,000 copies of survivin
mRNA as recommended by FDI. Parallel quantification of b-
actin, without the preamplification step, served as a quality
control. Samples with less than 1,000 copies of b-actin were
excluded.
Variant 2 (Invitek kit/FDI assay)
This variant was employed from October 2005 until March
2008 and was identical to variant 1, except for the RNA isolation
step. Here, instead of the RNeasy kit, an InviTrapH Spin Cell
RNA Mini Kit (Invitek) was used according to the manufacturer’s
protocol. The cut-off for survivin-positive samples was set to
40,000 copies of survivin mRNA.
Variant 3 (Invitek kit/IPA assay)
This variant was used from March 2008 until the end of the
study in 2010. RNA was isolated using the InviTrapH Spin Cell
RNA Mini Kit (Invitek), as in variant 2. The assay (IPA assay) to
quantify survivin and b-actin was very similar to the original FDI
assay used in variant 1 and 2, except for small differences in some
of the primers and probes [33]. Details of the assay are described
below. The cut-off for survivin-positive samples was raised to
100,000 copies of survivin mRNA.
Reverse transcription
In all assay variants cDNA was synthesized using a TaqManH
Reverse Transcription Reagent kit (Applied Biosystems, Foster
City, CA). The 25 ml reaction volume contained 2.5 ml1 0 6 RT
buffer, 5 ml MgCl2, 1.75 ml dNTP mixture, 0.75 ml random
hexamers, 1 ml oligo (dT)16,1ml RNase inhibitor, 1 ml reverse
transcriptase, and 12 ml RNA sample (or control). The reaction
was incubated at 42uC for 80 min and then heat inactivated at
95uC for 5 min.
Preamplification
The low abundance of survivin in urine samples required a
preamplification step. This step was not necessary for b-actin. The
following primers were used to amplify the survivin cDNA: 59-
ATG GGT GCC CCG ACG TTG CC-39 (forward) and 59-GCT
CCG GCC AGA GGC CTC AA-39 (reverse). The primers were
synthesized by Eurofins MWG Operon (Ebersberg, Germany) and
provided in a concentration of 5 pmol/ml (HPSF-purified). The
20 ml PCR reaction contained 10 ml2 6TaqManH Universal PCR
Master Mix with UNG (uracil-N-glycosylase) (Applied Biosystems),
1 ml forward primer, 1 ml reverse primer, 4 ml DEPC-treated H2O
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was programmed as follows: 1 cycle 50uC for 2 min and 95uC for
10 min, 20 cycles 95uC for 30 sec, 55uC for 1 min, and 72uC for
1 min.
Real-Time PCR
The preamplified cDNA of survivin and the cDNA of b-actin
were quantified by Real-Time PCR. Both LightCycler-based
measurements were carried out in parallel with an identical PCR
protocol: 1 cycle of 50uC for 2 min and 95uC for 10 min followed
by 45 cycles of 95uC for 15 sec and 60uC for 1 min. The primers
and probes were synthesized by Applied Biosystems with the
following sequences: 59-GAT GAC GAC CCC ATA GAG GAA
C-39 (survivin forward, 10 pmol/ml), 59-GGG TTA ATT CTT
CAA ACT GCT TCT-39 (survivin reverse, 10 pmol/ml), VIC-59-
TCC GGT TGC GCT TTC CTT TCT GTC-39-TAMRA
(survivin probe, 12 pmol/ml) and 59-CCT GGC ACC CAG CAC
AA-39 (b-actin forward, 10 pmol/ml), 59-GCC GAT CCA CAC
GGA GTA CT-39 (b-actin reverse, 10 pmol/ml), FAM-59-AAG
ATC AAG ATC ATT GCT CCT CCT GAG CG-39-TAMRA
(b-actin probe, 12 pmol/ml).
For the survivin quantification the 20 ml RT-PCR reaction
contained 10 ml2 6 TaqManH Universal PCR Master Mix
without UNG (Applied Biosystems), 2 ml survivin forward primer,
2 ml survivin reverse primer, 1 ml survivin probe, 1 mlH 2O (Roth),
0.4 ml BSA (10 mg/ml, Roche), and 3.6 ml preamplified cDNA of
survivin (or positive control, negative control, or standards of
survivin). For b-actin quantification the 20 ml reaction contained
10 ml2 6 TaqManH Universal PCR Master Mix with UNG
(Applied Biosystems), 2 ml b-actin forward primer, 2 ml b-actin
reverse primer, 1 ml b-actin probe, 1 mlH 2O (Roth), 0.4 ml BSA
(10 mg/ml, Roche), and 3.6 ml cDNA of b-actin (or positive
control, negative control, or standards of b-actin).
Recombinant survivin and b-actin cDNA were each subcloned
into a pDrive vector (Qiagen) and served as positive controls: A
dilution of about 10,000 copies of survivin mRNA (as well as a
separate reaction with about 10,000 copies of b-actin mRNA) was
run in parallel with each reverse transcription and the following
steps.
For the standard curve, standard A contained 100, standard B
1,000, standard C 10,000, standard D 100,000, and standard E
1,000,000 copies of survivin/b-actin cDNA (each). DEPC-treated
H2O (Roth) served as negative control.
Statistical analysis
Survivin was quantified in three assay variants. The logarithm
of survivin was standardized by subtracting the assay-specific mean
and dividing by the assay-specific standard deviation. For the
evaluation of the performance of survivin the last urine sample
during follow-up and for cases the last sample before diagnosis was
used. To evaluate potential predictors for a positive test result
multivariate generalized estimation equation (GEE) models were
applied. In these models the following parameters were included:
age in 10-year classes, smoking status (never vs. ever), prevalent
bladder cancer and bladder cancer observed during UroScreen,
diabetes mellitus, and urine status (creatinine, hematuria, and
leukocytes). Detailed data on urine status was available for a sub-
cohort. Hematuria and leukocytes were semi-quantitatively
assessed according to [36]. ROC curves and AUC values were
determined for the full dataset and different subsets. Cancer
predictive values were calculated for all tumors and subtypes with
95% confidence intervals (CI). All calculations were performed
with SAS/STAT and SAS/IML software, version 9.2 (SAS
Institute Inc., Cary, NC).
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